Abstracts tagged "juvenile idiopathic arthritis (JIA)"

Abstract Number: 2212 • 2013 ACR/ARHP Annual Meeting
Development Of Tools To Facilitate Shared Decision Making About Medications For Juvenile Idiopathic Arthritis – A Project Of The Pediatric Rheumatology Care and Outcomes Improvement Network
Esi Morgan DeWitt¹, Ellen A. Lipstein², Katie Staun³, Linda Scherer⁴, Janalee Taylor⁵, Carole M. Lannon⁴ and William B. Brinkman⁶, ¹Department of Pediatrics, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Division of Adolescent Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³University of Cincinnati, Cincinnati, OH, ⁴James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵William S. Rowe Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Division of General and Community Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Medication options for juvenile idiopathic arthritis (JIA) are increasing. Medications differ on a variety of attributes, including mechanisms of action, dosing intervals, modes of…
Abstract Number: 2191 • 2013 ACR/ARHP Annual Meeting
Intestinal Microbiome In Polyarticular Juvenile Idiopathic Arthritis: A PILOT Study
Petra C.E. Hissink Muller^1,2, A.E. Budding³, Cornelia F. Allaart⁴, Danielle M.C. Brinkman^1,5, Taco W. Kuijpers⁶, Michiel Westedt¹, J. Merlijn van den Berg⁷, Lisette W.A. Van Suijlekom-Smit⁸, Marion A.J. Van Rossum⁹, Tim G.J. de Meij¹⁰ and Rebecca Ten Cate¹, ¹Pediatric Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Pediatric Rheumatology, Reade Institute, Amsterdam, Netherlands, ³Department of Medical Microbiology and Infection Control, VU University Medical Center, Amsterdam, Netherlands, ⁴Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Pediatric Rheumatology, Rijnland Hospital, Leiderdorp, Netherlands, ⁶Pediatric Rheumatology and Immunology, Emma Children's Hospital/Academic Medical Center (AMC), Amsterdam, Netherlands, ⁷Department of Pediatric Rheumatology and Immunology, Emma Children's Hospital / Academic Medical Center (AMC), Amsterdam, Netherlands, ⁸Pediatric Rheumatology, Erasmus MC Sophia Children's Hospital, Rotterdam, Netherlands, ⁹Department of Pediatric Rheumatology and Immunology, Emma Children's Hospital / Academic Medical Center and Reade Institute, Amsterdam, Netherlands, ¹⁰Pediatric Gastroenterology, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: The intestinal microbiome may play a role in the pathogenesis of Juvenile Idiopathic Arthritis (JIA). In IBD patients an overall decrease in microbial diversity of…
Abstract Number: 2192 • 2013 ACR/ARHP Annual Meeting
Vitamin D Receptor Polymorphisms In A Cohort Of Italian Patients With Juvenile Idiopathic Arthritis
Fernanda Falcini¹, Francesca Marini², Donato Rigante³, Federico Bertini⁴, Gemma Lepri⁵, Stefano Stagi⁶, Marco Matucci Cerinic⁷ and Maria Luisa Brandi⁸, ¹Department of Biomedicine, Division of Rheumatology AOUC, Excellence Centre for Research, Florence, Italy, ²Surgery and Translational Medicine, University of Florence, Firenze, Italy, ³Pediatrics, Università Cattolica Sacro Cuore, Rome, Italy, ⁴Department of Internal Medicine, Rheumatology Section, University of Florence, Florence, Italy, ⁵Department of Internal Medicine, Section of Rheumatology, Transition Clinic, University of Florence, Florence, Italy, ⁶Pediatric Endocrinology Unit, Anna Meyer Children’s Hospital, University of Florence, Firenze, Italy, ⁷Department of Biomedicine, Division of Rheumatology, University of Florence, Florence, Italy, ⁸Surgery and Translational Medicine, University of Florence, Florence, Italy
Background/Purpose: A role for vitamin D has been hypothesized in generating disease activity for patients with juvenile idiopathic arthritis (JIA): specific polymorphisms of vitamin D…
Abstract Number: 2207 • 2013 ACR/ARHP Annual Meeting
Plasma Cytokine Concentrations Are Associated With Folate Perturbations and Methotrexate Polyglutamate Accumulation In The Peripheral Blood Of Juvenile Idiopathic Arthritis Patients Treated With Low-Dose Methotrexate
Ryan S. Funk¹, Leon van Haandel¹, Marcia Chan², Lanny J. Rosenwasser², Andrew Lasky³, Maria F. Ibarra⁴, Mark F. Hoeltzel⁵, J.S. Leeder¹ and Mara L Becker⁶, ¹Clinical Pharmacology and Medical Toxicology, Children's Mercy Hospital, Kansas City, MO, ²Pediatric Immunology Research, Children's Mercy Hospital, Kansas City, MO, ³Pediatrics Rheumatology, Children's Mercy Hospital, Kansas City, MO, ⁴Pediatric Rheumatolgy, Children's Mercy Hospital, Kansas City, MO, ⁵Rheumatology Section, Children's Mercy Hospital, Kansas City, MO, ⁶Clinical Pharmacology and Rheumatology, Children's Mercy Hospital, Kansas City, MO
Background/Purpose: Methotrexate inhibits the production of inflammatory cytokines, but is also an antifolate. The activity of MTX is thought to depend on the formation of…
Abstract Number: 2208 • 2013 ACR/ARHP Annual Meeting
Psychological Condition Of JIA Patients Treated With Biologic Agents. – A Nation-Wide Survey In Japan
Yuki Osako¹, Yukiko Nonaka², Harumi Akaike², Tomohiro Kubota³, Tsuyoshi Yamatou², Tomokazu Nagakura⁴, Junko Yasumura⁵, Hiroyuki Imanaka² and Syuji Takei⁶, ¹School of Health Sciences, Faculty of Medicine,Department of Maternal & Child Nursing and Midwifery, Kagoshima University, Kagoshima city, Japan, ²Department of Pediatrics, Kagoshima University Hospital, Kagoshima, Japan, ³Dept of Pediatrics, Faculty of Medicine, Kagoshima University, Kagoshima, Japan, ⁴Department of Pediatrics, House of Meguminoseibo, Usuki, Japan, ⁵Dept of Pediatrics, Graduate School of Biomedical Sciences, Faculty of Medicine, Hiroshima University, Hiroshima City, Japan, ⁶School of Health Sciences, Faculty of Medicine, Kagoshima University, Kagoshima, Japan
Background/Purpose: Biologic agents, newly developed medications targeting for inflammatory cytokines such as TNF-alpha or IL-6, have been drastically improving the disease course of JIA who…
Abstract Number: 2168 • 2013 ACR/ARHP Annual Meeting
Temporomandibular Joint Involvement and Quality Of Life In Juvenile Idiopathic Arthritis
Paula Frid^1,2, Ellen Nordal^3,4, Francesca Bovis⁵, Denise Marafon⁵, Donato De Angelis⁵, Sheila Oliveira⁵, Fabrizia Corona⁵, Gabrieli Simonini⁵, Joyce Davidson⁵, Helen Foster⁵, Rik Joos⁵, Ivan Foeldvari⁵, Michel Steenks⁵, Pekka Lahdenne⁵, Pavla Dolezalova⁵, Elena Palmisani⁵, Alberto Martini⁵, Angela Pistorio⁵ and Nicolino Ruperto⁵, ¹Department of Otorhinolaryngology, Division of Oral and Maxillofacial Surgery, University Hospital North Norway, Tromso, Norway, ²Public Dental Service Competence Centre of Northen Norway, Tromso, Norway, ³Department of Clinical Medicine, University of Tromsø, Tromsø, Norway, ⁴Department of Pediatrics, University Hospital of North Norway, Tromsø, Norway, ⁵Istituto Giannina Gaslini, Pediatria II, Reumatologia, Paediatric Rheumatology International Trials Organisation (PRINTO) Coordinating Center, Genoa, Italy, Genoa, Italy
Background/Purpose: Temporomandibular joint (TMJ) arthritis in childhood is seen in a substantial percentage of children with Juvenile idiopathic arthritis (JIA) and may lead to reduced mouth…
Abstract Number: 1780 • 2013 ACR/ARHP Annual Meeting
The Randomized Placebo Phase Study of Rilonacept in the Treatment of Systemic Juvenile Idiopathic Arthritis
Norman T. Ilowite¹, Kristi Prather², Yuliya Lokhnygina³, Laura E. Schanberg⁴, Melissa Elder⁵, Diana Milojevic⁶, James W. Verbsky⁷, Steven J. Spalding⁸, Yukiko Kimura⁹, Lisa F. Imundo¹⁰, Marilynn G. Punaro¹¹, David D. Sherry¹², Stacey E. Tarvin¹³, Lawrence S. Zemel¹⁴, James D. Birmingham¹⁵, Beth S. Gottlieb¹⁶, Michael L. Miller¹⁷, Kathleen M. O'Neil¹⁸, Natasha M. Ruth¹⁹, Carol A. Wallace²⁰, Nora G. Singer²¹ and Christy I. Sandborg²², ¹Pediatrics, The Children's Hospital at Montefiore, Bronx, NY, ²Statistics, Duke Clinical Research Institute, Durham, NC, ³Duke Clinical Research Institute, Durham, NC, ⁴Pediatrics, Duke University Medical Center, Durham, NC, ⁵Pediatrics, University of Florida, Gainesville, HI, ⁶Dept of Pediatric Rheumatology, University of California, San Francisco, San Francisco, CA, ⁷Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, ⁸Pediatric Institute, Department of Pediatric Rheumatology, The Cleveland Clinic, Cleveland, OH, ⁹Pediatric Rheumatology, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ¹⁰Pediatric and Adult Rheumatology Columbia University Medical Center, New York, NY, ¹¹Pediatric Rheumatology, Texas Scottish Rite Hospital, Dallas, TX, ¹²Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ¹³Pediatric Rheumatology, Riley Hospital for Children, Indianapolis, IN, ¹⁴Pediatric Rheumatology Collaborative Study Group, Cincinnati, OH, ¹⁵Medicine & Pediatrics, Rheumatology, Michigan State University College of Human Medicine, Grand Rapids, MI, ¹⁶Pediatric Rheumatology, Cohen Children's Medical Center of New York, New Hyde Park, NY, ¹⁷Rheumatology, Childrens Memorial Hospital, Chicago, IL, ¹⁸Division of Pediatric Rheumatology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁹Pediatric Rheumatology, Medical University of South Carolina, Charleston, SC, ²⁰University of Washington School of Medicine and Seattle Children's Hospital, Seattle, WA, ²¹Rheumatology, MetroHealth Medical Center, Cleveland, OH, ²²Pediatric Rheumatology, Stanford University, Palo Alto, CA
Background/Purpose: The RAndomized Placebo Phase Study Of Rilonacept in the Treatment of Systemic Juvenile Idiopathic Arthritis (RAPPORT) is a multicenter controlled trial using a…
Abstract Number: 790 • 2013 ACR/ARHP Annual Meeting
Predictors and Sustainability Of Clinical Inactive Disease In Polyarticular Juvenile Idiopathic Arthritis Given Aggressive Therapy Very Early In The Disease Course
Carol A. Wallace¹, Edward H. Giannini², Steven J. Spalding³, Philip J. Hashkes⁴, Kathleen M. O'Neil⁵, Andrew S. Zeft⁶, Ilona S. Szer⁷, Sarah Ringold⁸, Hermine Brunner⁹, Laura E. Schanberg¹⁰, Robert P. Sundel¹¹, Diana Milojevic¹², Marilynn G. Punaro¹³, Peter Chira¹⁴, Beth S. Gottlieb¹⁵, Gloria C. Higgins¹⁶, Norman T. Ilowite¹⁷, Yukiko Kimura¹⁸, Anne Johnson⁹, Bin Huang¹⁹ and Daniel J. Lovell², ¹University of Washington School of Medicine and Seattle Children's Hospital, Seattle, WA, ²Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Pediatric Institute, Department of Pediatric Rheumatology, The Cleveland Clinic, Cleveland, OH, ⁴Pediatrics, Shaare-Zedek Medical Center, Jerusalem, Israel, ⁵Pediatric Rheumatology, Riley Hospital for Children, Indianapolis, IN, ⁶Pediatric Institute, Department of Pediatric Rheumatology, Cleveland Clinic Foundation, Cleveland, OH, ⁷Div of Rheumatology, Rady Childrens Hosp San Diego, San Diego, CA, ⁸Pediatrics, Seattle Children's Hospital/Univ of Washington, Seattle, WA, ⁹Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁰Pediatrics, Duke University Medical Center, Durham, NC, ¹¹Division of Immunology, Boston Children's Hospital, Boston, MA, ¹²Dept of Pediatric Rheumatology, University of California, San Francisco, San Francisco, CA, ¹³Pediatric Rheumatology, Texas Scottish Rite Hospital, Dallas, TX, ¹⁴Pediatric Rheumatology, Indiana University School of Medicine, Riley Hospital for Children, Indianapolis, IN, ¹⁵Pediatric Rheumatology, Cohen Children's Medical Center of New York, New Hyde Park, NY, ¹⁶Pediatric Rheumatology Ohio State University, Nationwide Childrens Hosp, Columbus, OH, ¹⁷Pediatrics, The Children's Hospital at Montefiore, Bronx, NY, ¹⁸Pediatric Rheumatology, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ¹⁹Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center/University of Cincinnati School of Medicine, Cincinnati, OH
Background/Purpose: The double-blind, randomized placebo-controlled Trial of Early Aggressive Therapy in Polyarticular Juvenile Idiopathic Arthritis (TREAT) compared the ability of 2 aggressive treatment regimens to…
Abstract Number: 280 • 2013 ACR/ARHP Annual Meeting
Long-Term Safety and Efficacy Of Etanercept In Paediatric Subjects With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Or Psoriatic Arthritis
Tamas Constantin¹, Ivan Foeldvari², Jelena Vojinovic³, Gerd Horneff⁴, Ruben Burgos-Vargas⁵, Irina Nikishina⁶, Jonathan Akikusa⁷, Tadej Avcin⁸, Jeffrey Chaitow⁵, Elena Koskova⁹, Bernard Lauwerys¹⁰, Jack Bukowski¹¹, Chuanbo Zang¹², Joseph Wajdula¹², Deborah Woodworth¹², Bonnie Vlahos¹³, Alberto Martini¹⁴ and Nicolino Ruperto⁵, ¹Semmelweis University, Budapest, Hungary, ²Department of Pediatric Rheumatology, Hamburger Zentrum für Kinder und Jugendrheumatologie, Hamburg, Germany, ³Dept Pediatric Rheumatology, Clinical Center, School of Medicine University of Nis, Nis, Serbia, ⁴Department of Pediatrics, Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ⁵PRINTO, Genoa, Italy, ⁶Pediatric Department, Scientific Research Institute of Rheumatology RAMS, Moskow, Moskow, Russia, ⁷Rheumatology, Royal Childrens Hospital, Parkville, Australia, ⁸The Ljubljana University Medical Centre, Pediatric Clinic, Ljubljana, Slovenia, ⁹National Institute of Rheumatic Diseases, Piestany, Slovakia, ¹⁰Pôle de Maladies Rhumatismales, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, ¹¹Department of Specialty Care, Pfizer Inc, Collegeville, PA, ¹²Pfizer Inc., Collegeville, PA, ¹³Department of Specialty Care, Pfizer Inc., Collegeville, PA, ¹⁴Pediatria II, Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: Etanercept (ETN) is approved for the treatment of pediatric patients with the polyarticular subtype of juvenile idiopathic arthritis (JIA). In addition, based on the…
Abstract Number: 283 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Biologic Treatments In Juvenile Idiopathic Arthritis With a Polyarticular Course: An Indirect Comparison
Laura Sawyer¹, Alex Diamantopoulos², Hermine Brunner³, Fabrizio De Benedetti⁴, Nicolino Ruperto⁵, Fred Dejonckheere⁶ and Caroline Keane⁷, ¹Symmetron Limited, London, United Kingdom, ²Symmetron Limited, Herts, United Kingdom, ³PRCSG, Cincinnati, OH, ⁴Division of Rheumatology, Department of Pediatric Medicine, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ⁵PRINTO, Genoa, Italy, ⁶F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁷Roche, Welwyn Garden City, United Kingdom
Background/Purpose: To date there are no head-to-head trials comparing the efficacy of biologic treatments for polyarticular-course JIA (pcJIA). The purpose of this study was to…
Abstract Number: 284 • 2013 ACR/ARHP Annual Meeting
What Is the Relative Priority of the ACR Pediatric Core Set Measures for Youth With Juvenile Idiopathic Arthritis and Their Parents?
Jaime Guzman¹, Oralia Gomez-Ramirez², Susanne M. Benseler³, Roberta A. Berard⁴, Rollin Brant⁵, Ciaran M. Duffy⁶, Roman Jurencak⁷, Kiem Oen⁸, Ross E. Petty⁹, Natalie J. Shiff¹⁰ and Lori B. Tucker¹¹, ¹Pediatric Rheum/Rm K4-122, BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ²Anthropology, University of British Columbia, Vancouver, BC, Canada, ³Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Children's Hospital of Western Ontario, London, ON, Canada, ⁵Statistics, University of British Columbia, Vancouver, BC, Canada, ⁶Rheumatology, Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, ⁷University of Ottawa, Ottawa, ON, Canada, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹Pediatric Rheumatology, BC Children's Hosptial, Vancouver, BC, Canada, ¹⁰Pediatric Rheumatology, University of Saskatchewan, Saskatoon, SK, Canada, ¹¹Rheumatology, BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada
Background/Purpose: The ACR has endorsed a core set of six measures to assess the course of JIA and the impact of treatment: active joint count,…
Abstract Number: 290 • 2013 ACR/ARHP Annual Meeting
Children With JIA Show Distinct Patterns Of Improvement In Their Health-Related Quality Of Life During The First Year On Treatment: Growth Mixture Modeling Of a Prospective Cohort Of Newly Diagnosed Patients
Bin Huang¹, Chen Chen², Stacey Niehaus³, Hermine Brunner⁴, Rina Mina⁵ and Michael Seid⁶, ¹Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center/University of Cincinnati School of Medicine, Cincinnati, OH, ²Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Cincinnati Children's Hospital Medical Center/University of Cincinnati School of Medicine, Cincinnati, OH, ⁵Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Pulmonary, Cincinnati Children's Hospital Medical Center/University of Cincinnati School of Medicine, Cincinnati, OH
Background/Purpose: Health-related quality of life (HRQOL) is a key outcome in clinical care and research for children with JIA. Despite excellent clinical control and the…
Abstract Number: 1597 • 2012 ACR/ARHP Annual Meeting
Efficacy and Safety of Tocilizumab in Patients with Polyarticular Juvenile Idiopathic Arthritis: Data From a Phase 3 Trial
Hermine Brunner¹, Nicolino Ruperto², Zbigniew Zuber³, Caroline Keane⁴, Olivier Harari⁵, Andrew Kenwright⁴, Rubén J. Cuttica⁶, Vladimir Keltsev⁷, Ricardo Xavier³, Inmaculada Calvo Penades⁷, Irina Nikishina⁸, Nadina Rubio-Perez⁹, Ekaterina Alekseeva¹⁰, Vyacheslav Chasnyk¹¹, Jose Chavez³, Gerd Horneff¹², Violetta Opoka-Winiarska³, Pierre Quartier¹³, Clovis A. Silva⁷, Earl D. Silverman¹⁴, Alberto Spindler¹⁴, D. J. Lovell¹⁵, Alberto Martini¹⁴ and Fabrizio De Benedetti¹⁶, ¹Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Paediatric Rheumatology International Trials Organisation [PRINTO], Genova, Italy, ³PRINTO, Genoa, Italy, ⁴Roche, Welwyn Garden City, United Kingdom, ⁵Roche Products Ltd., Welwyn Garden City, United Kingdom, ⁶Hospital de Niños Pedro de Elizalde - University of Buenos Aires, Buenes Aires, Argentina, ⁷Paediatric Rheumatology International Trials Organisation–IRCCS [PRINTO], Genoa, Italy, ⁸Pediatric Department, Scientific Research Institute of Rheumatology RAMS, Moskow, Moskow, Russia, ⁹Hospital Universitario Dr. José Eleuterio Gonzalez, Monterrey, Mexico, ¹⁰Istituto Giannina Gaslini, Genoa, Italy, ¹¹Hospital Pediatry, State Pediatric Medical University, Saint-Petersburg, Russia, ¹²Department of Pediatrics, Centre of Pediatric Rheumatology, Sankt Augustin, Germany, ¹³Pediatria II, Istituto Giannina Gaslini, Genoa, Italy, ¹⁴Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH, ¹⁵Cincinnati Children's Hospital, Cincinnati, OH, ¹⁶PRINTO and PRSCG, Genoa, Italy
Background/Purpose: Elevated IL-6 levels are associated with disease activity in patients (pts) with juvenile idiopathic arthritis (JIA).1 Tocilizumab (TCZ), an IL-6 receptor inhibitor, was evaluated…
Abstract Number: 123 • 2012 ACR/ARHP Annual Meeting
Detection of Synovitis in Clinically Inactive Juvenile Idiopathic Arthritis Patients by Ultrasonography with POWER Doppler
Paz Collado¹, MariLuz Gamir², Rosa Merino³, Consuelo Modesto⁴, Indalecio Monteagudo⁵ and Juan Carlos Lopez-Robledillo⁶, ¹Rheumatology, Severo Ochoa University Hospital, Madrid, Spain, ²Rheumatology, Ramon y Cajal University Hospital, Madrid, Spain, ³Hospital Universitario La Paz, Madrid, Spain, ⁴Hospital Valle de Hebron, Barcelona, Spain, ⁵Rheumatology, Gregorio Marañón Hospital, Madrid, Spain, ⁶Hospital Niño Jesus, Madrid, Spain
Background/Purpose: The advances in therapeutic effectiveness have created a need for looking for imaging tools that describe more precisely the clinical state of disease inactivity.…
Abstract Number: 1157 • 2012 ACR/ARHP Annual Meeting
The Phenotypic Characterization of Juvenile Idiopathic Arthritis in African American Children
Lauren Minor¹, Lori Ponder², Emily G. Ferrell³, Sheila Angeles-Han¹, Christine W. Kennedy⁴, Kelly A. Rouster-Stevens¹, Mina Pichavant¹, Larry B. Vogler³ and Sampath Prahalad¹, ¹Pediatrics, Emory University School of Medicine, Atlanta, GA, ²Children's Healthcare of Atlanta, Atlanta, GA, ³Emory University School of Medicine, Atlanta, GA, ⁴Rheumatology Immunology, Emory Children's Center, Atlanta, GA
Background/Purpose: JIA, a common childhood arthropathy, with an estimated prevalence of 1 in 1000 in children under the age of 16, affects children of all…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].